



Irene A Burger

Contact

Irene A Burger

Publications (11)

Wälti S, Skawran S, Sartoretti T, Schwyzer M, Gennari A, Mader C, Treyer V, Kellenberger C, Burger I, Hany T, Maurer A, Huellner M, Messerli M. A third of the radiotracer dose: two decades of progress in pediatric [F]fluorodeoxyglucose PET/CT and PET/MR imaging. *Eur Radiol* 2023

Sartoretti T, Skawran S, Gennari A, Maurer A, Euler A, Treyer V, Sartoretti E, Wälti S, Schwyzer M, von Schulthess G, Burger I, Huellner M, Messerli M. Fully automated computational measurement of noise in positron emission tomography. *Eur Radiol* 2023

Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. *Swiss Med Wkly* 2023; 153:40108.

Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger I, Müller J. Focal unspecific bone uptake on [F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. *Eur J Nucl Med Mol Imaging* 2021; 48:4483-4494.

Gnesin S, Prior J, Treyer V, Kaufmann P, Ametamey S, Schibli R, Müller C, Choschzick M, Früh M, Siano M, Meisel A, Burger I, Müller J, Schaefer N. Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer. *EJNMMI Res* 2020; 10:32.

Ferraro D, Hermanns T, Kaufmann P, Omlin A, Kranzbühler H, Gablinger R, Müller A, Müller J, Eberli D, Muehlematter U, Garcia Schüler H, Burger I. Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. *Eur J Nucl Med Mol Imaging* 2019

Rupp N, Schibli R, Eberli D, Huber G, Morand G, Messerli M, Ferraro D, Muehlematter U, Müller J, Töpfer A, Lenggenhager D, Pizzuto D, Umbricht C, Burger I. First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands. *J Nucl Med* 2019

Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüler H, Muehlematter U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. *Eur J Nucl Med Mol Imaging* 2018

Sekine T, Veit-Haibach P, von Schulthess G, Kollias S, Huber G, Ter Voert E, Stolzmann P, Burger I, Delso G, Barbosa F, Huellner M. Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. *Head & neck* 2017; 39:1550-1558.

Sekine T, Veit-Haibach P, von Schulthess G, Kollias S, Huber G, Stolzmann P, Burger I, Kuhn F, de Galiza Barbosa F, Huellner M. PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. *Clin Imaging* 2017; 42:232-239.

Müller J, Hüllner M, Strobel K, Huber G, Burger I, Haerle S. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction. *Laryngoscope* 2015; 125:1861-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch